Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent

Biochemical and Biophysical Research Communications

Volumn 470, Issue 2, 2016, Pages 324-330

  Cheng, Feng ^a   Wang, Lingling ^a   Shen, Yunfeng ^a   Xia, Jun ^a   Chen, Heng ^a   Jiang, Yuanqiang ^a   Lu, Mize ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Apoptosis; mTOR; WYE 687

Indexed keywords

ANTILEUKEMIC AGENT; CASPASE 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN BCL XL; PROTEIN S6; UNCLASSIFIED DRUG; WYE 687; MTOR PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; WYE-687;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EVALUATION STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCID MOUSE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; MALE; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, SCID; PYRAZOLES; PYRIMIDINES; TOR SERINE-THREONINE KINASES;

EID: 84956581640     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.01.054     Document Type: Article

References (28)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J. Clin. 62 2012 10 29
3. S. Park, N. Chapuis, J. Tamburini, V. Bardet Cornillet-Lefebvre, L. Willems, A. Green Mayeux, C. Lacombe, and D. Bouscary Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia Haematologica 95 2010 819 828
4. F. Callera, C.O. Lopes, E.S. Rosa, and C.C. Mulin Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome Leuk. Res. 32 2008 1633 1634
5. C. Recher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V.M. Mas, D. Benzaquen, G. Laurent, F. Huguet, and B. Payrastre Antileukemic activity of rapamycin in acute myeloid leukemia Blood 105 2005 2527 2534
6. Q. Xu, S.E. Simpson, T.J. Scialla, A. Bagg, and M. Carroll Survival of acute myeloid leukemia cells requires PI3 kinase activation Blood 102 2003 972 980
7. J. Dancey mTOR signaling and drug development in cancer Nat. Rev. Clin. Oncol. 7 2010 209 219
8. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat. Rev. Cancer 6 2006 729 734
9. E. Vilar, J. Perez-Garcia, and J. Tabernero Pushing the envelope in the mTOR pathway: the second generation of inhibitors Mol. Cancer Ther. 10 2011 395 403
10. K. Yu, L. Toral-Barza, C. Shi, W.G. Zhang, J. Lucas, B. Shor, J. Kim, J. Verheijen, K. Curran, D.J. Malwitz, D.C. Cole, J. Ellingboe, S. Ayral-Kaloustian, T.S. Mansour, J.J. Gibbons, R.T. Abraham Nowak, and A. Zask Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin Cancer Res. 69 2009 6232 6240
11. L. Yang, W. Weng, Z.X. Sun, X.J. Fu, J. Ma, and W.F. Zhuang SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo Biochem. Biophys. Res. Commun. 460 2015 903 908
12. Y.M. Zhang, Z.Q. Zhang, Y.Y. Liu, X. Zhou, X.H. Shi, Q. Jiang, D.L. Fan, and C. Cao Requirement of Galphai1/3-Gab1 signaling complex for keratinocyte growth factor-induced PI3K-AKT-mTORC1 activation J. Invest. Dermatol. 135 2015 181 191
13. C. Li, J.F. Cui, M.B. Chen, C.Y. Liu, F. Liu, Q.D. Zhang, J. Zou, and P.H. Lu The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent Cancer Biol. Ther. 16 2015 34 42
14. H.Z. Huo, Z.Y. Zhou, B. Wang, J. Qin, W.Y. Liu, and Y. Gu Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014 Biochem. Biophys. Res. Commun. 443 2014 406 412
15. M. Shimobayashi, and M.N. Hall Making new contacts: the mTOR network in metabolism and signalling crosstalk Nat. Rev. Mol. Cell Biol. 15 2014 155 162
16. J. Averous, B.D. Fonseca, and C.G. Proud Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1 Oncogene 27 2008 1106 1113
17. A. Toschi, E. Lee, N. Gadir, M. Ohh, and D.A. Foster Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2 J. Biol. Chem. 283 2008 34495 34499
18. K. Tanaka, I. Babic, D. Nathanson, D. Akhavan, D. Guo, B. Gini, J. Dang, S. Zhu, H. Yang, J. De Jesus, A.N. Amzajerdi, Y. Zhang, C.C. Dibble, H. Dan, A. Rinkenbaugh, W.H. Yong, H.V. Vinters, J.F. Gera, W.K. Cavenee, T.F. Cloughesy, B.D. Manning, A.S. Baldwin, and P.S. Mischel Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance Cancer Discov. 1 2011 524 538
19. M. Kim, N. Kim, V.D. D'Agati, C.W. Emala Sr., and H.T. Lee Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1-phosphate-dependent pathways Am. J. Physiol. Ren. Physiol. 293 2007 F1827 F1835
20. Y. Chiba, H. Takeuchi, H. Sakai, and M. Misawa SKI-II, an inhibitor of sphingosine kinase, ameliorates antigen-induced bronchial smooth muscle hyperresponsiveness, but not airway inflammation, in mice J. Pharmacol. Sci. 114 2010 304 310
21. H.Y. Zhou, and S.L. Huang Current development of the second generation of mTOR inhibitors as anticancer agents Chin. J. Cancer 31 2012 8 18
22. A. Gomez-Pinillos, and A.C. Ferrari mTOR signaling pathway and mTOR inhibitors in cancer therapy Hematol. Oncol. Clin. North Am. 26 2012 483 505 vii
23. B.I. Rini, and M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol. 10 2009 992 1000
24. G. Powis, and L. Kirkpatrick Hypoxia inducible factor-1alpha as a cancer drug target Mol. Cancer Ther. 3 2004 647 654
25. B. Zheng, J.H. Mao, L. Qian, H. Zhu, D.H. Gu, X.D. Pan, F. Yi, and D.M. Ji Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma Cancer Lett. 357 2015 468 475
26. S.J. Jiang, and S. Wang Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo Tumour Biol. 36 2015 8177 8184
27. C. Frelin, V. Imbert, E. Griessinger, A.C. Peyron, N. Rochet Philip, C. Dageville, A. Sirvent, M. Hummelsberger, E. Berard, M. Dreano, N. Sirvent, and J.F. Peyron Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells Blood 105 2005 804 811
28. M.L. Guzman, S.J. Neering, D. Upchurch, B. Grimes, D.S. Howard, D.A. Rizzieri, S.M. Luger, and C.T. Jordan Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells Blood 98 2001 2301 2307